Patented respiratory imaging platform developer 4DMedical Limited (ASX:4DX) has delivered the first XV Lung Ventilation Analysis Software (XV LVAS) scan to an Australian patient.
The scan was successfully completed in Victoria and marks the first commercial use of XV LVAS as the Company begins to roll out its infrastructure nationally. Installation of XV LVAS is anticipated in hospitals and imaging centres in Victoria as well as other states from early 2021.
As part of the national rollout, hospitals and imaging centres will be able to offer 4DMedical’s lung report in both inpatient and outpatient settings – maximising the number of addressable patients in Australia.
The delivery of the first XV LVAS scan comes after the company received TGA approval for the technology, six months ahead of schedule, in September 2020.
Utilising 4DMedical’s proprietary XV Technology, XV LVAS converts sequences of X-ray images into four- dimensional quantitative data by using patented mathematical models and algorithms. XV LVAS is the Company’s first Software-as-a-Service (SaaS) offering and can provide immediate benefits to Australian physicians and patients, including assisting in the ability for physicians to diagnose respiratory diseases earlier and with more sensitivity while using existing hospital and clinical equipment.
We’re pleased to hit yet another milestone ahead of schedule and see our end-to-end SaaS clinical solution perform flawlessly in a real-world setting,” Andreas Fouras, Founder & CEO of 4DMedical said.
“COVID-19 has seen traditional spirometry assessments shut down and our technology also provides an excellent alternative for patients who need regular and more detailed lung health assessments.
“While this might be our first ever Australian patient report, we expect to scale up quickly and begin to make a real difference to lung health in Australia.”
